March 7 (Reuters) - Cardiome Pharma Corp COM.TO
* Reports FY 2016 revenue $25.3 million
* Cardiome reports fourth quarter and full year 2016 financial results
* Q4 revenue $7.0 million versus I/B/E/S view $6.3 million
* Q4 loss per share $0.18
* Reports FY 2016 revenue up 21 percent
* Q4 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S
* Believe Xydalba sales in 2017, followed by Trevyent launch in 2018/19 will be start of strong revenue growth for years to come Source text for Eikon: ID:nPnbjsPJ8a Further company coverage: COM.TO